肺癌脑转移治疗的新进展

Research progress in treatment of lung cancer with brain metastases

摘要:

脑转移瘤是颅内最常见的恶性肿瘤,其原发灶多来源于肺。肺癌患者一旦发生脑转移,预后差,病死率高。自然生存期约1～2个月,如经积极治疗,其中位生存期也仅有4～12个月。目前研究显示,脑转移肺癌患者的预后与影像学技术、放疗技术、手术方式等密切相关。近年来,随着放疗技术的提高、手术方式的改进、以及靶向药物的不断开发利用,患者的生存时间有了很大延长,生活质量也有了明显提高。本文从肺癌脑转移的放疗、化疗、手术治疗及小分子靶向治疗4个方面系统阐释肺癌脑转移治疗的研究进展。

Abstract:

Metastatic encephaloma is the most common malignant tumor in the brain, and most primary tumors originate in the lungs. Brain metastasis of lung cancer results in poor prognosis and high mortality rate, with a natural survival of about 1-2 months and median survival of only 4-12 months even after active treatment. Current studies have shown that the prognosis of lung cancer patients with brain metastasis is closely related to imaging technology, radiotherapy technology, and surgical modality. With the improvement of radiotherapy technology and surgical methods, and the continuous development and utilization of targeted drugs in recent years, the survival of the patients has been largely prolonged, and the life quality has been significantly improved. This paper reviews systematically the research progress in brain metastasis of lung cancer in the aspects of radiotherapy, chemotherapy, surgical treatment and small molecule targeted treatment.